Tesamorelin 20mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of Tesamorelin supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF092025036

Key analytical results include:

• Assay Content: 20.8 mg
• Identification – Retention Time: 0.992
• Identification – Spectrum: 988
• Purity: 99.0 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

Tesamorelin is a synthetic peptide research compound frequently studied in controlled laboratory environments investigating growth hormone signalling pathways and endocrine regulatory systems.

The peptide belongs to a class of growth hormone releasing hormone (GHRH) analogues that interact with receptors involved in endocrine signalling networks.

This preparation contains 20 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide structure and stable analytical profile, Tesamorelin has become a widely referenced compound in experimental endocrine research models.

Compound Overview

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH), a peptide responsible for stimulating growth hormone signalling pathways within the endocrine system.

GHRH interacts with receptors located primarily in the pituitary gland where it plays a role in regulating growth hormone secretion.

Research involving Tesamorelin frequently explores peptide-mediated endocrine signalling pathways and hormone regulatory mechanisms.

Due to its defined molecular structure and receptor interaction profile, Tesamorelin is widely utilised in laboratory studies examining hormonal regulatory systems.

Historical Background and Scientific Context

Scientific research into growth hormone regulation expanded significantly during the late twentieth century as researchers identified complex endocrine signalling networks responsible for hormone secretion.

During this period, growth hormone releasing hormone (GHRH) was identified as a key regulatory peptide controlling growth hormone signalling pathways.

Advances in peptide synthesis allowed researchers to develop synthetic analogues such as Tesamorelin to investigate these pathways in controlled laboratory environments.

These compounds are now widely used in experimental models studying endocrine signalling and hormone regulation mechanisms.

Mechanistic Focus in Research

Within experimental laboratory settings, Tesamorelin is commonly studied in relation to growth hormone regulatory pathways.

Research investigations commonly explore the compound in experimental models examining:

• Growth hormone signalling pathways
• GHRH receptor interaction mechanisms
• Endocrine regulatory network modelling
• Peptide-mediated hormonal signalling processes
• Comparative secretagogue research
• Hormonal regulatory feedback systems
• Endocrine signalling pathway analysis

These experimental models allow scientists to investigate molecular mechanisms that influence endocrine signalling and hormonal regulation.

Research Applications

In controlled research environments, Tesamorelin may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated hormone regulation.

Examples of research applications include:

• Growth hormone signalling studies
• Endocrine regulatory pathway investigation
• Hormonal signalling network analysis
• Secretagogue interaction research
• Comparative peptide compound evaluation
• Intracellular signalling pathway modelling
• Controlled in vitro endocrine research

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Purity 99.0% with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin level below 0.001 EU per mg
• Batch GF092025036 – Published October 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.